Martin Besser

Consultant Haematologist
Cambridge University Hospitals NHS Foundation Trust

Presentation(s):

• PB0052 - Assessing Endothelial Activation and Risk of Bleeding in patients receiving VV-ECMO supportive therapy for COVID-19 using non-standard laboratory assays

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0304 - Low ADAMTS13 activity rapid assay results in patients with low clinical probability of Thrombotic Thrombocytopaenic Purpura (TTP) – the United Kingdom experience

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0305 - Method and laboratory specific clinical cut-offs support appropriate interpretation of ADAMTS13 activity assays

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0600 - ADAMTS13 activity and non-parallel vWF Ristocetin CoFactor activity are associated with severity of COVID-19 infection

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1067 - Pre-analytical screening and removal of Argatroban interference for Haemostasis assays

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1068 - Dilute Thrombin Time versus activated Partial thromboplastin Time to monitor Argatroban in critically ill patients.

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1396 - Validation of clinical reference ranges for viscoelastometric assessment of haemostasis (TEG® 6S) and standard laboratory tests in obstetric patients

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM